search
Back to results

Medixair® System on Surgical Site Infection in Cardiac Patients

Primary Purpose

Surgical Site Infection

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Medixair®
Sponsored by
University of Valladolid
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Surgical Site Infection focused on measuring cardiac surgery, risk factors, infection

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients admitted to Postoperative Cardiac Intensive Care Unit after Cardiac Surgery with Extracorporeal Circulation

Exclusion Criteria:

  • Not signing informed consent

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Medixair®

    NO Medixair®

    Arm Description

    Cardiac reanimation unit bed with Medixair®

    Cardiac reanimation unit bed with NO Medixair®

    Outcomes

    Primary Outcome Measures

    Infection rates after cardiac surgery
    To assess if there are fewer catheter infections, less bacteraemia, fewer urinary infections, fewer surgery site infections, fewer pneumonias in patients who have spent their first days after a heart surgery in a box with the Medixair system than without it.

    Secondary Outcome Measures

    Number of infected patients
    Number of infected patients
    mortality rate
    mortality rate
    number of patients with pneumonia
    number of patients with pneumonia

    Full Information

    First Posted
    May 4, 2015
    Last Updated
    September 24, 2015
    Sponsor
    University of Valladolid
    Collaborators
    Hospital Clínico Universitario de Valladolid
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02492919
    Brief Title
    Medixair® System on Surgical Site Infection in Cardiac Patients
    Official Title
    Impact of Medixair® System on Surgical Site Infection in Patients Admitted Into the Postoperative Cardiac Intensive Care Unit
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2011 (undefined)
    Primary Completion Date
    January 2015 (Actual)
    Study Completion Date
    January 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Valladolid
    Collaborators
    Hospital Clínico Universitario de Valladolid

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    There is a growing incidence of sepsis and septic shock in people after surgery, for which there may be several reasons: more elderly people and more severe illnesses are entering operating theatres, more invasive systems are being used to take care of patients in intensive care units, etc... Sepsis and septic shock are the most prevalent illnesses which cause the highest mortality in intensive care units. The incidence of this illness is 500,000 / year in the USA, and 240-400 / 100,000 persons in Europe. So this is a subject of great interest in hospitals and also to the National Health System (to both health workers and the health authorities) as a lot of money is spent on this illness. Since the 19th century, ultraviolet rays have been known to be able to sterilize microorganisms (to kill them); yet no ultraviolet system machine has been on the market, until now, to control nosocomial infections. The Medixair system, which aims to do this, has recently come on to the market. It uses C-ultraviolet rays, which are the strongest kind of ultraviolet rays to kill microorganisms. Thus, it is of interest to know whether this system is good enough to lower infections in intensive care units. It is logical to believe that the the fewer the micro-organisms, the lower the possibilities of infection.
    Detailed Description
    Study design Prospective, comparative, randomized, non intervention study Patients Patients older than 18 years Cardiac Surgery anesthetized using Extracorporeal Circulation Randomization There are 10 independent boxes at the Postoperative Cardiac Intensive Care Unit. (Each of these boxes have single beds). Every year, the Cardiac Reanimation Unit of our hospital received 500 patients, post heart surgery. After getting the permissions needed to make the research, the Medixair® system has been placed in 5 of these units, and the comparison group will be the other 5 beds without Medixair®. Patients have been assigned randomly to either (Medixair® and NO Medixair®). The endpoint is: -To compare the infection rates after a cardiac surgery, on patients located in boxes with and without a Medixair® system. The aim is to see if there are fewer catheter infections, less bacteraemia, fewer urinary infections, less site of surgery infections, and fewer pneumonias in patients who have spent their first days after a heart surgery in a box with Medixair® system than without it. The infection rates in the intensive care unit will be followed, as well as the whole stay at hospital, as there might be fewer infections if there were fewer microorganisms around. Other objectives are: Identifying preoperative, intraoperative and postoperative risk factors to develop an infection illness after cardiac surgery, as well as which increase the length of stay at hospital and the mortality rate. Making an economic study of using this system against not using it. A further aim is to measure the following variables: Dependent variables (Outcome variables): infection 2º Outcome variables: colonization Independent variables will be a risk factor for infection: Preoperative: age, sex, any preoperative illness, immunosuppressor treatment, including corticosteroids. Intraoperative: antibiotic prophylaxis, surgical technique, length of cardiopulmonary bypass, length of aorta clamped, temperature during cardiopulmonary bypass, hematocrit at the end of cardiopulmonary bypass. Postoperative: length with mechanical ventilation, time spent in hospital, time spent in an intensive care unit, any organ complication (pulmonary insufficiency, renal failure, low cardiac index), septicemia, invasive techniques used, positive microorganism cultures. All of the patients will be treated in the same way Estimated number of patients Nowadays, the infection rate after cardiac surgery is around 5%, so following the current hypothesis that the Medixair® system, because of its ultraviolet emissions, is going to lower the infection rate after cardiac surgery, 419 patients are needed in each group to be able to demonstrate a significative 5% reduction in infection rates, with an alpha error of 0.05 and a beta error of 0.2 to have a power of 80%. As this is a preliminary study, in order to demonstrate a 5% reduction in the infection rate, half the number of patients (half of 419) will be used. As the patient volume is 500 a year, the number will be rounded up to 500, in order to be able to consider a complete year.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Surgical Site Infection
    Keywords
    cardiac surgery, risk factors, infection

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    1000 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Medixair®
    Arm Type
    Experimental
    Arm Description
    Cardiac reanimation unit bed with Medixair®
    Arm Title
    NO Medixair®
    Arm Type
    No Intervention
    Arm Description
    Cardiac reanimation unit bed with NO Medixair®
    Intervention Type
    Device
    Intervention Name(s)
    Medixair®
    Intervention Description
    Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
    Primary Outcome Measure Information:
    Title
    Infection rates after cardiac surgery
    Description
    To assess if there are fewer catheter infections, less bacteraemia, fewer urinary infections, fewer surgery site infections, fewer pneumonias in patients who have spent their first days after a heart surgery in a box with the Medixair system than without it.
    Time Frame
    3 weeks
    Secondary Outcome Measure Information:
    Title
    Number of infected patients
    Description
    Number of infected patients
    Time Frame
    3 weeks
    Title
    mortality rate
    Description
    mortality rate
    Time Frame
    3 weeks and for the whole stay at hospital
    Title
    number of patients with pneumonia
    Description
    number of patients with pneumonia
    Time Frame
    3 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    99 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients admitted to Postoperative Cardiac Intensive Care Unit after Cardiac Surgery with Extracorporeal Circulation Exclusion Criteria: Not signing informed consent
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Eduardo Tamayo, PhD, MD
    Organizational Affiliation
    Hospital Clínico Universitario de Valladolid
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Medixair® System on Surgical Site Infection in Cardiac Patients

    We'll reach out to this number within 24 hrs